The research, conducted by a team based at Shanghai Children’s Hospital and Shanghai Children’s Medical Centre affiliated with Shanghai Jiao Tong University School of Medicine, was published in BMC Pediatrics. The investigators set out to solve two intertwined problems that have hampered earlier attempts to use molecular markers for Kawasaki disease. The first is the absence of a standardized reference gene for normalizing microRNA measurements, a technical gap that makes results difficult to compare across laboratories and patient cohorts. The second is the lack of a rigorously validated clinical model that combines molecular signals with the everyday measurements clinicians already collect at the bedside.

MicroRNAs are short, non-coding RNA molecules, roughly eighteen to twenty-five nucleotides in length, that fine-tune gene expression after transcription. Platelets, the small cell fragments best known for their role in blood clotting, carry a rich cargo of these regulatory molecules. Because platelets are deeply involved in the vascular inflammation that defines Kawasaki disease, their microRNA profile offers a molecular window into the disease process itself. Previous work had implicated platelet microRNAs in the pathogenesis of the illness, but without a reliable normalization strategy, the field lacked the reproducibility needed to translate those signals into a usable diagnostic tool.

The study unfolded in two carefully sequenced phases. In the first, the researchers evaluated three candidate reference microRNAs in forty children, applying three complementary statistical algorithms—geNorm, NormFinder, and BestKeeper—to determine which candidate held steadiest across samples. The winner was miR-126-3p, a microRNA well known for its roles in vascular biology and endothelial integrity. Establishing miR-126-3p as the most stable reference gene matters because quantitative reverse transcription polymerase chain reaction, the workhorse technique used to measure microRNA abundance, produces meaningful numbers only when samples are normalized against a reference whose expression does not shift with disease state. Without that anchor, apparent differences between patients and controls can be artifacts of measurement rather than biology.

With the reference gene secured, the team moved to the second phase, enrolling 120 children: sixty with Kawasaki disease and sixty febrile controls, that is, children with fever but without the disease. The febrile control group is critical to the study’s design, because the central diagnostic dilemma in real clinical practice is distinguishing Kawasaki disease from the many other childhood infections and inflammatory conditions that also present with fever. The researchers quantified twelve platelet microRNAs using qRT-PCR, normalizing each measurement against miR-126-3p. Seven of the twelve microRNAs were significantly upregulated in the children with Kawasaki disease, a pattern consistent with the idea that platelets actively participate in the inflammatory cascade rather than serving as passive bystanders.

Identifying differentially expressed microRNAs, however, is only half the task. The harder question is whether a combination of these molecular signals and ordinary clinical variables can reliably sort sick children into the right diagnostic category. To answer it, the team turned to machine learning. They built five different predictive models and used least absolute shrinkage and selection operator, or LASSO, regression to perform feature selection—a statistical technique that shrinks the influence of less informative variables toward zero, effectively winnowing the field down to the features that genuinely carry diagnostic weight. This step guards against overfitting, the common failure mode in which a model memorizes the quirks of its training data rather than learning patterns that generalize to new patients.

The standout performer was a support vector machine model, an algorithm that finds the optimal boundary separating two classes of data points in a high-dimensional space. When the selected microRNAs were combined with routine clinical indicators, the optimized model achieved an area under the receiver operating characteristic curve of 0.944, with a 95 percent confidence interval of 0.748 to 0.969. In practical terms, the area under the curve measures how well a model distinguishes diseased from non-diseased patients across all possible diagnostic thresholds, with 1.0 representing perfect discrimination. The model reached a sensitivity of 0.889, meaning it correctly identified nearly nine of every ten children with Kawasaki disease, and a specificity of 0.833, correctly clearing about five of every six children who did not have the disease.

Just as important as those headline numbers is where the model held up. The researchers assessed performance using tenfold cross-validation, a technique in which the data are repeatedly split so that every patient serves at some point as an unseen test case, and they examined calibration and decision curve analysis to confirm that the model’s predicted probabilities were trustworthy and clinically useful. Crucially, performance remained robust in two of the hardest subgroups: children evaluated within the first five days of fever, when clinical signs are still emerging, and children with incomplete Kawasaki disease, who lack the full constellation of classic symptoms. Incomplete cases are precisely the ones most likely to be missed and most likely to suffer coronary artery complications as a result of delayed treatment.

The clinical implications are considerable. Intravenous immunoglobulin, the standard treatment for Kawasaki disease, dramatically reduces coronary damage when given within the first ten days of illness, and the benefit is greatest the earlier therapy begins. A diagnostic tool that works in the earliest days of fever and in incomplete presentations could therefore shorten the dangerous interval between symptom onset and treatment. The study’s authors caution that their model was internally validated, meaning it was tested within the same cohort used to build it, and external validation in independent, geographically distinct populations will be needed before the approach enters routine practice. Still, the combination of a rigorously selected reference gene, a febrile control group, and disciplined machine learning methodology gives the finding a solidity that many biomarker studies lack.

Beyond the immediate diagnostic promise, the work reinforces a broader shift in pediatric medicine toward molecularly informed decision-making. Platelets are easy to obtain from a routine blood draw, and qRT-PCR is an established technology available in many hospital laboratories, which means the barrier to translating this research into a clinical assay is lower than for many emerging diagnostics. If future external validation confirms these results, a platelet microRNA panel could become a practical adjunct to clinical judgment, helping physicians act quickly for the children who need it most and avoid unnecessary interventions for those who do not. For a disease whose greatest danger lies in being recognized too late, that would represent a meaningful advance.

Subject of Research: Platelet microRNA-based clinical model for early diagnosis of Kawasaki disease in children

Article Title: Platelet miRNAs for early diagnosis of Kawasaki disease: development and internal validation of a clinical model

Article References: Zhou, Y., Chen, L., Chen, L., Xiao, T., Fu, L., Wu, J., Li, G., Liu, J., Zhang, C., Song, S., & Huang, M. (2026). Platelet miRNAs for early diagnosis of Kawasaki disease: development and internal validation of a clinical model. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07673-x

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07673-x

Keywords: Kawasaki disease, platelet miRNAs, miR-126-3p, diagnostic model, machine learning, support vector machine, LASSO, qRT-PCR, early diagnosis, coronary artery complications, pediatrics, BMC Pediatrics

Kawasaki disease is an acute systemic vasculitis, meaning that inflammation affects blood vessels throughout the body. It occurs primarily in infants and young children and can involve the coronary arteries, which supply blood to the heart. Fever, changes in the mouth and eyes, skin eruptions, and swelling of the hands and feet are among its characteristic clinical features, but the presentation can vary. If inflammation is not controlled, injury to the coronary arteries may result in aneurysms or other long-term cardiovascular complications. The disease is not classified as a conventional viral infection, although infectious and immune triggers have long been investigated.

The study by Huang, Kuo, Yu and colleagues focuses on exosomes found in urine. Exosomes are extracellular vesicles, typically tens to hundreds of nanometres in diameter, that are released by many types of cells. They carry molecular cargo, including proteins, lipids, messenger RNAs and microRNAs, and can transport this material between cells. Because exosomes are protected by a lipid membrane, their contents may remain relatively stable in body fluids. Urine is also obtained non-invasively, making urinary exosomes particularly attractive for pediatric research and for repeated sampling during the course of an illness.

MicroRNAs are short, non-coding RNA molecules that regulate gene activity after transcription. Rather than providing instructions for building proteins, they bind to specific messenger RNAs and can reduce or alter the production of proteins involved in cellular processes. A single microRNA may influence multiple genes, while several microRNAs can act together on pathways governing immunity, blood-vessel function, tissue repair and inflammation. In Kawasaki disease, such regulatory networks could reflect the intense activation of immune cells and the vascular changes associated with systemic inflammation.

Unlike many blood-based biomarkers, urinary exosomal microRNAs may provide information from several biological systems at once. Exosomes released by tissues can enter the circulation and eventually be filtered or excreted through the kidneys. Their molecular cargo may therefore offer an indirect window into inflammation occurring beyond the urinary tract. At the same time, urinary signals must be interpreted carefully because they can be influenced by kidney function, hydration, age, urine concentration and other biological variables. Normalizing measurements and distinguishing disease-related changes from technical or physiological variation are important components of exosome research.

The investigation is significant because it considers not only whether particular urinary microRNAs are associated with Kawasaki disease, but also how those signals change after treatment. This temporal perspective is central to clinical biomarker development. A molecule that differs between children with Kawasaki disease and healthy children may help with diagnosis, but a marker that rises or falls in parallel with inflammation could be more useful for monitoring recovery. Dynamic changes may also help identify children whose vascular inflammation persists despite an initial clinical improvement.

Treatment for Kawasaki disease is aimed at rapidly suppressing the inflammatory response and reducing the risk of coronary-artery damage. Clinical decisions are currently based on symptoms, physical findings, laboratory tests and cardiac imaging, including echocardiography. These tools remain essential, but they do not always provide a complete molecular picture of the disease. Urinary exosomal microRNAs could eventually complement existing assessments by offering a minimally invasive way to follow immune and vascular activity over time. Any such application would require validation in larger and more diverse groups of patients.

The researchers’ work also illustrates how extracellular vesicles are becoming important in precision medicine. Because exosomes reflect the cells that produce them, their contents may change as inflammation begins, intensifies or resolves. However, identifying a useful biomarker requires more than detecting a statistical difference. Scientists must determine whether a microRNA is reproducibly measurable, whether its change is specific to Kawasaki disease, whether it predicts coronary complications or treatment resistance, and whether the result can be translated into a practical clinical test. The study’s emphasis on post-treatment changes provides a foundation for these future questions.

By examining urinary exosomal microRNAs in children with Kawasaki disease and tracking their behavior after therapy, Huang and colleagues contribute to a growing effort to understand the molecular course of pediatric vasculitis. The findings may help clarify how systemic inflammation is reflected in urine and whether exosomal signals can serve as non-invasive indicators of disease activity. Further studies will be needed to establish the biological origin and clinical value of the identified microRNAs, but the approach points toward a future in which a simple urine sample could support more individualized monitoring of children at risk of cardiovascular complications.

Subject of Research: Urinary exosomal microRNAs in Kawasaki disease and their changes after treatment

Article Title: Urinary exosomal microRNAs in Kawasaki disease and their changes after treatment

Article References: Huang, HC., Kuo, HC., Yu, HR. et al. Urinary exosomal microRNAs in Kawasaki disease and their changes after treatment. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05337-1

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05337-1

Keywords: Kawasaki disease; urinary exosomes; microRNAs; pediatric vasculitis; inflammation; biomarkers; treatment response